Yahoo! Finance: Biotechnology Industry News: CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

CytRx Reaches Patient Enrollment Target in Global Phase 2b Clinical Trial with Tamibarotene as First-Line Treatment for Non-Small-Cell Lung Cancer Feb 28th 2013, 13:30 [Business Wire] - CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, announced that enrollment of 140 evaluable patients has been comple

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions